facebook

Consistent Bleed Protection That Fits Your Lifestyle

Zero spontaneous bleeds (median AsBR) regardless of
age and dosing schedule in hemophilia A clinical trials

  • Shown in children, adolescents, and adults when treated with AFSTYLA as prophylaxis
  • Overall annualized bleeding rates (median ABR) were 1.14 in adults and adolescents and 3.69 in children
purple connector

Proven bleed protection with AFSTYLA twice weekly in adults and adolescents*

ZERO INHIBITORS

Adults and adolescents

ZERO Spontaneous bleeds (median AsBR)

ZERO Annualized bleeds (median ABR)

ZERO Joint bleeds (median AjBR)

*FDA approved for dosing 2 to 3 times a week.

As a paramedic, Cody can’t let a bleed distract him from his job

"When it comes to my job, that could mean somebody's life."

–Cody switched to AFSTYLA

†Speaker's personal experience. Individual results may vary.

What different ways were
bleeds measured?

  • Annualized spontaneous bleeding rate (AsBR) shows the number of spontaneous bleeds, or bleeds that happen without an obvious cause, over a year
  • Annualized bleeding rate (ABR) shows the number of bleeds that happen over a year for any reason
  • Annualized joint bleeding rate (AjBR) shows the number of bleeds that happen over a year in a joint

Dependable bleed control when you need it

On-demand Factor VIII treatment

In clinical trials, the majority of bleeds successfully resolved with 1 infusion

In clinical trials, the majority of bleeds successfully resolved with 1 infusion


On-demand chart: bleeds were controlled with 1 to 2 infusions of AFSTYLA

In the remaining 6% of participants over 12 years old, bleeds were controlled with 3 or more infusions. In children under 12 years old, 3.5% of bleeds were controlled with 3 or more infusions. One child had no response.

Presurgery and postsurgery control

100% of surgeries had excellent or good bleeding control

With AFSTYLA, surgical bleeding control was rated "excellent" in 15 surgeries and "good" in 1 surgery.

You are now leaving the current website.

Do you want to continue?

No Yes